SPUTNIK V

Vaccine Overview

Human Adenovirus Vector (Ad 5) and Vector (Ad 26) Platform

Vaccine does not contain live human adenoviruses, but contains human adenovirus based vectors that cannot multiply in the body and are completely safe
The approach of the Gamaleya Center with the vaccine using the most prudent prime-boost (two doses) vaccination regimen with two vector serotypes: number 5 (Ad5) and number 26 (Ad26) has a clear advantage over the one-vector approach used by other pharmaceutical companies
The vaccine induces strong cell immune response forming antigen specific cells of both populations of T-lymphocytes: T-helper (CD4+) and T-killer (CD8+)
It has elicited IgG response in 100% immunized volunteers in mean titers significantly higher than titers of COVID-19 convalescents

A vector is a virus that lacks a gene responsible for reproduction and is used to transport genetic material from another virus that is being vaccinated against into cell
A gene coding S-protein of SARS-COV-2 spikes is inserted into each vector

Vector (Ad 26) with a gene coding S-protein of coronavirus gets into
cell vaccinated against into cell
As cell synthesizes S-protein, the development of immunity begins

Another vaccination with Vector (Ad 5) takes place in 21 days
The vaccine based on another adenovirus vector unknown to the body boosts the immune response and provides long-lasting immunity

A breakthrough idea of using two different types of adenovirus vectors